EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Laryngeal Cancer Microbiome Study Reveals Parvimonas and Campylobacter as Potential Therapy Targets

Hetal Lad iD, Avi Shah, Emma R Thompson iD, Sumayya Javid, Ruey Horng Chee, Sydney Zaransky, Aatin Dhanda, Avleen Mudhar, Sagar Lamichhane, Abigail T Chua, Kristy Bono, Jamie Bono und 4 weitere

The Laryngoscope · 05.11.2026

DOI: 10.1002/lary.71027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 05.11.2026. Verfasst von Hetal Lad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Jersey Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Laryngeal cancer accounts for 40% of head and neck malignancies and 1% of all cancer‐related deaths worldwide. We evaluated the laryngeal cancer microbiome to identify cancer‐specific genera as potential treatment targets.

Methods

A prospective study was conducted using 57 laryngeal mucosal samples from 24 treatment‐naive laryngeal cancer patients and 33 patients who were undergoing otolaryngological surgery unrelated to oral or laryngeal diseases (01/2023–09/2025). DNA was extracted and amplified in triplicate, targeting the V3/V4 region of the 16S rRNA gene, followed by paired‐end 2 × 300 bp sequencing on the Illumina NextSeq 2000. Amplicon sequence variants were identified via DADA2 and assigned to genera using a naive Bayes classifier. Two samples with zero classified read pairs were excluded.

Results

Most patients were male (87.5% cancer, 66.7% controls) and smokers (83.3% cancer, 54.5% controls). Cancer patients' core laryngeal microbiomes uniquely contained Parvimonas (3.67%; 95% CI: 0.70%–6.64%), and Campylobacter (1.12%; 95% CI: 0.60%–1.63%), while control patients' uniquely contained Corynebacterium (2.97%; 95% CI: 0.00%–7.67%) and Alloprevotella (1.34%; 95% CI: 0.64%–2.04%). Cancer samples were significantly enriched in 19 genera, notably Peptococcus (2.93, q = 0.0003), Campylobacter (1.68, q = 0.009), and Parvimonas (2.02, q = 0.03), compared to controls.

Conclusions

Laryngeal cancer patients' samples displayed microbial dysbiosis, with enrichment of microbes present in gastrointestinal cancers, cervical cancer, and inflammatory states; they also exhibited loss of immunoprotective taxa. These findings support that microbiome profiling can distinguish malignant mucosa and guide future studies targeting genera increased in cancer, including Parvimonas and Campylobacter . Level of Evidence 3.

Schlagwörter

Stichwörter der Autor:innen

CampylobacterParvimonas16S rRNAlaryngeal cancermicrobiome

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
  • Division of Infectious Disease, Center for Data Science, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
  • Department of Oral Biology, Rutgers Health School of Dental Medicine, Newark, New Jersey, USA.
  • Rutgers School of Graduate Studies, Newark, New Jersey, USA.
  • Department of Otolaryngology Head and Neck Surgery, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

ORCID-Profile: Hetal Lad, Emma R Thompson, Rachel Kaye

Förderung

  • New Jersey Health Foundation

Zitieren

APA

Lad, H., Shah, A., Thompson, E. R., Javid, S., Chee, R. H., Zaransky, S., Dhanda, A., Mudhar, A., Lamichhane, S., Chua, A. T., Bono, K., Bono, J., Kaye, R., Johnson, W. E., Cugini, C., & Yan, K. (2026). Laryngeal Cancer Microbiome Study Reveals Parvimonas and Campylobacter as Potential Therapy Targets. The Laryngoscope. https://doi.org/10.1002/lary.71027

Vancouver

Lad H, Shah A, Thompson ER, Javid S, Chee RH, Zaransky S, et al. Laryngeal Cancer Microbiome Study Reveals Parvimonas and Campylobacter as Potential Therapy Targets. The Laryngoscope. 2026. doi:10.1002/lary.71027

BibTeX
@article{Lad2026,
  author = {Lad, Hetal and Shah, Avi and Thompson, Emma R and Javid, Sumayya and Chee, Ruey Horng and Zaransky, Sydney and Dhanda, Aatin and Mudhar, Avleen and Lamichhane, Sagar and Chua, Abigail T and Bono, Kristy and Bono, Jamie and Kaye, Rachel and Johnson, W Evan and Cugini, Carla and Yan, Kenneth},
  title = {Laryngeal Cancer Microbiome Study Reveals Parvimonas and Campylobacter as Potential Therapy Targets},
  journal = {The Laryngoscope},
  year = {2026},
  doi = {10.1002/lary.71027}
}
Kostenlos starten →